[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100530260":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":10,"centralContacts":19,"locations":26,"responsibleParty":48,"collaborators":10,"id":52,"slug":53,"hasResults":54,"nctId":55,"briefTitle":56,"officialTitle":57,"acronym":58,"eligibilityCriteria":59,"healthyVolunteers":54,"sex":60,"minAge":61,"maxAge":62,"enrollmentInfo":63,"targetDuration":10,"studyType":66,"phases":10,"briefSummary":67,"conditions":68,"keywords":71,"overallStatus":29,"whyStopped":10,"lastUpdateSubmitDate":77,"lastUpdatePostDateStruct":78,"startDateStruct":81,"completionDateStruct":83,"leadSponsor":85,"locationsCount":86},{"fullName":5,"class":6},"Consorci Sanitari de Terrassa","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"prostate patient",null,"use of Leupreline",[13],"Other: ACETATE LEUPRELINE",[15],{"type":6,"name":16,"description":17,"armGroupLabels":18,"otherNames":10},"ACETATE LEUPRELINE","USE ACETATE LEUPRELINE BEFORE AND AFTER PROSTATE DELIMITATION",[9],[20,25],{"name":21,"role":22,"phone":23,"phoneExt":10,"email":24},"nicolas feltes","CONTACT","619-819-9500","nicofeltes_81@hotmail.com",{"name":21,"role":22,"phone":10,"phoneExt":10,"email":24},[27],{"facility":28,"status":29,"city":30,"state":31,"zip":32,"country":33,"countryCode":34,"cosmosGeoPoint":35,"geoPoint":40,"contacts":41},"Hospital de Terrassa","RECRUITING","Terrassa","Barcelona","08225","Spain","ES",{"type":36,"coordinates":37},"Point",[38,39],2.01667,41.56667,{"lat":39,"lon":38},[42,44,46],{"name":43,"role":22,"phone":23,"phoneExt":10,"email":24},"MANUEL GALDEANO",{"name":43,"role":45,"phone":10,"phoneExt":10,"email":10},"SUB_INVESTIGATOR",{"name":47,"role":45,"phone":10,"phoneExt":10,"email":10},"SATURIO PAREDES",{"type":49,"investigatorFullName":50,"investigatorTitle":51,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"PRINCIPAL_INVESTIGATOR","Nicolas Feltes","M.D","100530260","prostatic-size-reduction-following-of-leuprorelin-acetate-100530260",false,"NCT06184464","Prostatic Size Reduction Following of Leuprorelin Acetate","Prostatic Size Reduction Following the Administration of Leuprorelin Acetate in Localized Prostate Cancer Prior to Radiation Therapy. Pilot Study.","PROSTSIZE","Inclusion Criteria:\n\nMan with Prostate positive biopsy. Able to Ssgned informed consent form. Need of hormonal treatment before start of radiotherapy\n\nExclusion Criteria:\n\nPatients With prostate size of less than 20 cc at diagnosis. Patients With Positive lymph nodes or metastatic prostate cancer disease on imaging studies.\n\nPatients with Previous pelvic radiation therapy.","MALE","18 Years","95 Years",{"count":64,"type":65},40,"ESTIMATED","OBSERVATIONAL","To determine the possible reduction in prostate size following the administration of Leuprelin prior to the application of radiotherapy.",[69,70],"Prostate Cancer Adenocarcinoma","Prostate Adenocarcinoma",[72,73,74,75,76],"reduccion","Eligard","leupreline","radiotherapy","feltes","2024-09-09",{"date":79,"type":80},"2024-09-19","ACTUAL",{"date":82,"type":80},"2024-02-02",{"date":84,"type":65},"2024-12-15",{"name":5,"class":6},1]